161 related articles for article (PubMed ID: 30360707)
1. Insulin-like Growth Factor I Receptor: A Novel Target for Hepatocellular Carcinoma Gene Therapy.
Wang L; Yao M; Zheng W; Fang M; Wu M; Sun J; Dong Z; Yao D
Mini Rev Med Chem; 2019; 19(4):272-280. PubMed ID: 30360707
[TBL] [Abstract][Full Text] [Related]
2. IGF-I receptor as an emerging potential molecular-targeted for hepatocellular carcinoma in vitro and in vivo.
Yao M; Wang L; Yang J; Yan X; Cai Y; Yao D
Tumour Biol; 2016 Nov; 37(11):14677-14686. PubMed ID: 27623941
[TBL] [Abstract][Full Text] [Related]
3. Autocrine insulin-like growth factor-II stimulation of tumor cell migration is a progression step in human hepatocarcinogenesis.
Nussbaum T; Samarin J; Ehemann V; Bissinger M; Ryschich E; Khamidjanov A; Yu X; Gretz N; Schirmacher P; Breuhahn K
Hepatology; 2008 Jul; 48(1):146-56. PubMed ID: 18537183
[TBL] [Abstract][Full Text] [Related]
4. IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage.
Tovar V; Alsinet C; Villanueva A; Hoshida Y; Chiang DY; Solé M; Thung S; Moyano S; Toffanin S; Mínguez B; Cabellos L; Peix J; Schwartz M; Mazzaferro V; Bruix J; Llovet JM
J Hepatol; 2010 Apr; 52(4):550-9. PubMed ID: 20206398
[TBL] [Abstract][Full Text] [Related]
5. A pleiotropic effect of the single clustered hepatic metastamiRs miR-96-5p and miR-182-5p on insulin-like growth factor II, insulin-like growth factor-1 receptor and insulin-like growth factor-binding protein-3 in hepatocellular carcinoma.
Assal RA; El Tayebi HM; Hosny KA; Esmat G; Abdelaziz AI
Mol Med Rep; 2015 Jul; 12(1):645-50. PubMed ID: 25739014
[TBL] [Abstract][Full Text] [Related]
6. Lentivirus-mediated RNAi knockdown of insulin-like growth factor-1 receptor inhibits the growth and invasion of hepatocellular carcinoma via down-regulating midkine expression.
Bie CQ; Liu XY; Cao MR; Huang QY; Tang HJ; Wang M; Cao GL; Yi TZ; Wu SL; Xu WJ; Tang SH
Oncotarget; 2016 Nov; 7(48):79305-79318. PubMed ID: 27813495
[TBL] [Abstract][Full Text] [Related]
7. Insulin-like growth factor I is a comitogen for hepatocyte growth factor in a rat model of hepatocellular carcinoma.
Price JA; Kovach SJ; Johnson T; Koniaris LG; Cahill PA; Sitzmann JV; McKillop IH
Hepatology; 2002 Nov; 36(5):1089-97. PubMed ID: 12395318
[TBL] [Abstract][Full Text] [Related]
8. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
[TBL] [Abstract][Full Text] [Related]
9. [Molecular mechanisms of progression in human hepatocarcinogenesis].
Breuhahn K
Pathologe; 2010 Oct; 31 Suppl 2():170-6. PubMed ID: 20711584
[TBL] [Abstract][Full Text] [Related]
10. Serum from Chronic Hepatitis B Patients Promotes Growth and Proliferation via the IGF-II/IGF-IR/MEK/ERK Signaling Pathway in Hepatocellular Carcinoma Cells.
Ji Y; Wang Z; Chen H; Zhang L; Zhuo F; Yang Q
Cell Physiol Biochem; 2018; 47(1):39-53. PubMed ID: 29763915
[TBL] [Abstract][Full Text] [Related]
11. Down-regulating glypican-3 expression: molecular-targeted therapy for hepatocellular carcinoma.
Dong Z; Yao M; Wang L; Yang J; Yao D
Mini Rev Med Chem; 2014; 14(14):1183-93. PubMed ID: 25553423
[TBL] [Abstract][Full Text] [Related]
12. Abnormal expression of insulin-like growth factor-I receptor in hepatoma tissue and its inhibition to promote apoptosis of tumor cells.
Dong Z; Yao M; Wang L; Yan X; Gu X; Shi Y; Yao N; Qiu L; Wu W; Yao D
Tumour Biol; 2013 Dec; 34(6):3397-405. PubMed ID: 23797814
[TBL] [Abstract][Full Text] [Related]
13. Alteration of oncogenic IGF-II gene methylation status associates with hepatocyte malignant transformation.
Tai BJ; Yao M; Zheng WJ; Shen YC; Wang L; Sun JY; Wu MN; Dong ZZ; Yao DF
Hepatobiliary Pancreat Dis Int; 2019 Apr; 18(2):158-163. PubMed ID: 30692043
[TBL] [Abstract][Full Text] [Related]
14. Theranostical nanosystem-mediated identification of an oncogene and highly effective therapy in hepatocellular carcinoma.
Guo Y; Wang J; Zhang L; Shen S; Guo R; Yang Y; Chen W; Wang Y; Chen G; Shuai X
Hepatology; 2016 Apr; 63(4):1240-55. PubMed ID: 26680504
[TBL] [Abstract][Full Text] [Related]
15. [Abnormal expression of insulin-like growth factor-I receptor and inhibitory effect of its transcription intervention on nude mice xenograft tumor].
Yao M; Yan XD; Cai Y; Gu JJ; Yang XL; Pan LH; Wang L; Yao DF
Zhonghua Gan Zang Bing Za Zhi; 2016 Nov; 24(11):846-851. PubMed ID: 27978931
[No Abstract] [Full Text] [Related]
16. Overexpression of insulin-like growth factor-I receptor as a pertinent biomarker for hepatocytes malignant transformation.
Yan XD; Yao M; Wang L; Zhang HJ; Yan MJ; Gu X; Shi Y; Chen J; Dong ZZ; Yao DF
World J Gastroenterol; 2013 Sep; 19(36):6084-92. PubMed ID: 24106410
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of hepatocellular carcinoma cell growth by an anti-insulin-like growth factor-I receptor monoclonal antibody.
Yue L; Wang Y; Wang H; Gao H; Liang J; Sui A; Xiang J; Zhou F; Xu C; Zhao W; Liang W; Yao R
Oncol Rep; 2012 Oct; 28(4):1453-60. PubMed ID: 22895605
[TBL] [Abstract][Full Text] [Related]
18. Relationship of insulin-like growth factors system gene polymorphisms with the susceptibility and pathological development of hepatocellular carcinoma.
Weng CJ; Hsieh YH; Tsai CM; Chu YH; Ueng KC; Liu YF; Yeh YH; Su SC; Chen YC; Chen MK; Yang SF
Ann Surg Oncol; 2010 Jul; 17(7):1808-15. PubMed ID: 20119675
[TBL] [Abstract][Full Text] [Related]
19. Impact of insulin-like growth factor 2, insulin-like growth factor receptor 2, insulin receptor substrate 2 genes polymorphisms on susceptibility and clinicopathological features of hepatocellular carcinoma.
Rashad NM; El-Shal AS; Abd Elbary EH; Abo Warda MH; Hegazy O
Cytokine; 2014 Jul; 68(1):50-8. PubMed ID: 24656929
[TBL] [Abstract][Full Text] [Related]
20. Knockdown of insulin-like growth factor I receptor inhibits the growth and enhances chemo-sensitivity of liver cancer cells.
Zhang YW; Yan DL; Wang W; Zhao HW; Lu X; Wu JZ; Zhou JR
Curr Cancer Drug Targets; 2012 Jan; 12(1):74-84. PubMed ID: 22165963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]